AKT-IN-28

AKT-IN-28 (Compound L8) has a potent anti-proliferative activity (IC₅₀ s of 4.51, 4.57, 5.07, 8.94 and 6.59 μM for HCT-8, HCT-116, PC-3, MDA-MB-231, and HeLa cells, respectively), with low cytotoxicity in normal cells (IC₅₀ s of > 100  and 67 μM for MCF-10A and HCoEpiC cells)^[1].
AKT-IN-28 (1-4 μM, 24 h) dose-dependently decreases the Akt enzyme activity, and significantly inhibits the total Akt, p-Akt, PARP and β-catenin protein expression, cell proliferation activity and migration, while increase of cleaved-PARP protein level in HCT-8 and HCT-116 cells^[1].
AKT-IN-28 (0.25-1 μM, 7 days) significantly inhibites the viability of colon cancer cells with reduction of colony formation of HCT-116 cells^[1].
AKT-IN-28 (2-8 μM, 24 h) effectively induces cell apoptosis and arrests cell cycle in G2/M phase (8 μM) with decrease of cycle-related proteins CDH1, CDK1, and CDC20, and increases caspase3 activity in HCT-116 and HCT-8 cells^[1].
AKT-IN-28 (2-8 μM, 2-24 h) significantly reduces the glucose consumption, lactate production, and ATP level in HCT-116 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.